

Vimian has resolved to issue and repurchase class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares as part of its long-term incentive program 2025

At an Extraordinary General Meeting of Vimian Group AB (publ) ("Vimian") held on 11 June 2025, it was resolved to implement a long-term incentive program based on so-called hurdle shares and employee stock options ("LTIP 2025"). The Extraordinary General Meeting authorized the Board of Directors to resolve upon a new issue of class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares, and to repurchase the shares for further transfer to the participants in LTIP 2025. The Board of Directors has now, based on the authorizations granted by the Extraordinary General Meeting, resolved to carry out a new issue and subsequently repurchase a total of 1,762,823 shares, of which 1,067,263 class D shares, 231,847 class E1 2025 shares, 231,855 class E2 2025 shares and 231,858 E3 2025 shares.

As part of the implementation of LTIP 2025, 1,067,263 class D shares, 231,847 class E1 2025 shares, 231,855 class E2 2025 shares and 231,858 E3 2025 shares are issued to DNB Carnegie Investment Bank AB ("DNB Carnegie") at a subscription price corresponding to the quota value per share (approximately SEK 0.001668). The share capital is thereby increased by SEK 2,939,783,024. All issued shares will then, in accordance with the Board of Directors' resolution, be repurchased by Vimian from DNB Carnegie at the same price for further transfer to the participants in LTIP 2025 in accordance with the terms and conditions resolved upon by the Extraordinary General Meeting.

For further information, please contact:

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability

maria.tullberg@vimian.com

+46 73 626 88 86

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: www.vimian.com.

Press Release
27 October 2025 07:00:00 CET

Attachments

[Vimian has resolved to issue and repurchase class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares as part of its long-term incentive program 2025](#)